Patient-Funded Cancer Research

This is the authors' abstract. We don't add key points for this paper.

The introduction of a new medical treatment into clinical oncology has historically involved an institutional approach to drug development. Over the past 30 years, more than 500,000 compounds have been examined for anticancer activity; about 40 drugs (10 of which are moderately to highly effective) are now in clinical use.The development of anticancer drugs has involved institutions such as the National Cancer Institute (NCI), the pharmaceutical industry, and major university research centers. On average, the process has taken 10 years and $60 million to $90 million per drug. As founder and former director of the Biological Response Modifiers Program . . .